← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Tirzepatide × Cagrilintide × 2 of 4 selected View comparison

Tirzepatide

Dual incretin receptor agonist

Remove
VS

Cagrilintide

Long-acting amylin analogue

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target TirzepatideCagrilintide
✓ —
✓ —
— ✓

What These Compounds Share

Shared research line

All selected compounds are catalogued under Metabolic.

Shared pathway tags
Metabolic
Shared research areas
ObesityEnergy intake

Key Differences

Tirzepatide GIPR and GLP-1R are direct targets of Tirzepatide that none of the other selected compounds share. Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Cagrilintide AMYLIN is a direct target of Cagrilintide that none of the other selected compounds share. Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.

Compound Detail

Tirzepatide
What is it?
A lab-made peptide that mimics two natural gut hormones involved in blood sugar and appetite control.
What are people researching/using it for?
Approved and studied for type 2 diabetes and weight management.
Other uses being trialed
Sleep apnea linked to obesityHeart-related metabolic research
Worth knowing
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Activates GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon regulation, appetite and energy intake.
Synthetic acylated peptide · Synthetic analogue
Primary Targets & Biological System
Incretin / metabolic signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Activates both GIP and GLP-1 receptors -- the two incretin hormone receptors that respond when nutrients enter the gut, prompting the pancreas to release insulin in a glucose-dependent way (more when blood sugar is high, less when it isn't) and slowing gastric emptying, which contributes to reduced appetite. Combining both receptors' activity, rather than GLP-1R alone, is the specific mechanistic distinction from single-receptor GLP-1 agonists like semaglutide, and is what regulatory approvals for tirzepatide-based products have been built on for type 2 diabetes and weight management.
Research Areas
Type 2 diabetesObesityGlucose regulationEnergy intakeMetabolic disease
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Approximately 5 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Considerations
Research Limitations
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Alcohol and substance use
Dual GIP/GLP-1 agonism is being studied for effects on alcohol consumption, extending from the larger evidence base for GLP-1-only agonists like semaglutide -- early-stage relative to that body of work.
Fatty liver disease (MASLD/NAFLD)
Liver fat reduction has been an active secondary research area in tirzepatide metabolic trials.
Availability & Sources
Current Vital Edge Testing
Batch 1 · tested Oct 2026 · 99.878% purity, 35.12mg content Purity/ID report
Available As (Vital Edge Science)
Tirzepatide · A$179.95 A$199.95
Browse products →

Source review pending for this compound — no citation on file yet.

Cagrilintide
What is it?
A long-acting version of a natural hormone (amylin) that works alongside insulin to control appetite.
What are people researching/using it for?
Mainly studied for weight loss, often alongside GLP-1 medications.
Other uses being trialed
Combination therapy research alongside semaglutide/tirzepatide for obesity
Worth knowing
Often studied in combination with GLP-1 agonists rather than as a standalone agent.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Long-acting amylin analogue investigated for effects on satiety, food intake and metabolic physiology.
Acylated peptide analogue · Synthetic analogue
Primary Targets & Biological System
Amylin signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A long-acting analogue of amylin, a hormone co-released with insulin from the pancreas after eating. Amylin receptor activation is associated with slowed gastric emptying and central signalling that promotes satiety, working through a mechanism distinct from -- but often studied alongside -- the incretin pathway that GLP-1/GIP agonists use. Because amylin and GLP-1 signalling act on different receptor systems, cagrilintide is frequently investigated in combination with GLP-1 agonists rather than as a mechanistic substitute for them.
Research Areas
ObesityAppetiteSatietyEnergy intakeMetabolic research
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
159-195 hours (roughly 6.6-8.1 days), dose-dependent
Reported in a randomized Phase 1b trial (0.16-4.5 mg SC weekly doses, co-administered with semaglutide 2.4 mg); median Tmax 24-72 h, exposure proportional to dose.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Acts through the amylin system rather than GLP-1/GIP/glucagon receptor signalling.
Considerations
Research Limitations
Often studied in combination with GLP-1 agonists rather than as a standalone agent.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
Cagrilintide · A$159.95 A$179.95
Browse products →
View Research Sources (1) →
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
The Lancet, 2021 · Human Human · 95 exposed adults (96 randomized), phase 1b multiple-ascending-dose trial, BMI 27-39.9 · Subcutaneous, once weekly · PMID 33894838 · DOI 10.1016/S0140-6736(21)00845-X

Half-life 159-195h, median Tmax 24-72h, exposure proportional to dose; did not affect semaglutide exposure/elimination.

Supports: human_half_life

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.